bpc-157 multiple sclerosis study Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats Multifunctionality and Possible Medical Application

Treatment Protocol Dosage 250 to 500 mcg per day, physician-prescribed

Our delayed release formula enhances absorption, ensures ongoing support for the gut and joints

This is the standard choice for multi-dose peptide vials

Anti-inflammatory repair: inhibits the NF-B pathway and reduces the release of IL-6 induced by ultraviolet rays

PubMed PMID: 35013352

EBioMedicine 71:103503 Skillbck T, Delsing L, Synnergren J, Mattsson N, Janelidze S, Ngga K, Kilander L, Hicks R, Wimo A, Winblad B, Hansson O, Blennow K, Eriksdotter M, Zetterberg H (2017) CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients